

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/597,305
Filing Date	7/19/2006
First Named Inventor	CHOI, Inpyo
Art Unit	N/A
Examiner Name	N/A
Attorney Docket Number	58049-00034

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	OGAWA ET AL., "Expression of alpha4-Integrin Defines the Earliest Precursor of Hematopoietic Cell Lineage Diverged From Endothelial Cells," Blood 93(4): 1168-1177 (1999)	
	C2	KLEFSTROM ET AL., "c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors," Oncogene 18: 2181-2188 (1999)	
	C3	GUO ET AL., "A human Mix-like homeobox gene MIXL shows functional similarity to Xenopus Mix.1" Blood 100(1): 89-95 (2002)	
	C4	DAVIDSON, ALAN J. AND ZON, LEONARD I., "Turning Mesoderm into Blood: The Formulation of Hematopoietic Stem Cells during Embryogenesis," Current Topics in Developmental Biology 50: 45-60 (2000)	
	C5	Allen III et al., "c-Myb is essential for early T cell development," Genes & Dev. 13: 1073-1078 (1999)	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.